Approximately 1.5 million prostate biopsies are performed each year in the United States, yet the majority of them may be unnecessary, according to leading urologists. A negative biopsy result, while seeming like good news, actually exposes patients to infection risk and wasted healthcare resources. Meanwhile, biopsies that detect inconsequential prostate cancer burden patients with unnecessary stress and may lead to treatments they don't actually need. Now, researchers are testing a medication-based screening approach that could dramatically reduce how many men undergo this invasive procedure.

What Makes a Prostate Biopsy "Unnecessary"?

The problem with current prostate cancer screening practices is more nuanced than simply getting tested. A biopsy is considered unnecessary in two main scenarios: when it comes back negative, exposing the patient to procedural risks for no benefit, or when it detects what doctors call "inconsequential" prostate cancer, meaning cancer that is unlikely to cause harm during a man's lifetime.

When men receive a diagnosis of inconsequential prostate cancer, they face a difficult psychological burden. Knowing they have cancer, even if it's slow-growing and unlikely to threaten their life, often leads patients to pursue aggressive treatments like surgery or radiation therapy. These interventions carry their own risks and side effects, yet may provide no survival benefit for men with low-risk disease.

"A negative biopsy is bad because it puts the patient at risk and wastes money. When a patient is diagnosed with inconsequential prostate cancer because of the biopsy, the patient is now burdened with the stress of knowing they have cancer and may decide to undergo unbeneficial treatment," explained Ian M. Thompson, MD.

Ian M. Thompson, MD, Director and Professor, Department of Urology, Cancer Therapy & Research Center, The University of Texas Health Science Center

How Could a Medication Help Avoid Unnecessary Biopsies?

Researchers are investigating whether a short-term medication approach could serve as a screening tool to prevent unnecessary biopsies altogether. The strategy centers on finasteride, a medication commonly used to treat enlarged prostate and male pattern baldness. In a clinical trial currently underway, men who are eligible for a biopsy based on elevated PSA (prostate-specific antigen) levels are being randomly assigned to receive either a placebo or 3 months of 5-milligram finasteride.

The theory is straightforward: finasteride works by reducing PSA levels and shrinking prostate size. If the medication can lower these markers enough during the 3-month trial period, a biopsy may no longer be medically indicated. This approach could spare thousands of men from an invasive procedure while still identifying those who genuinely need further evaluation.

Steps to Understanding Your Prostate Cancer Screening Options

• Know Your PSA Baseline: PSA (prostate-specific antigen) is a protein produced by the prostate gland; elevated levels can indicate cancer risk, but they can also reflect benign conditions like infection or enlargement. Ask your doctor what your PSA level is and what it means for your individual risk profile.
• Discuss Biopsy Necessity: Before agreeing to a prostate biopsy, have a detailed conversation with your urologist about whether a biopsy is truly necessary based on your PSA level, age, family history, and overall health. Ask specifically whether your risk profile warrants an invasive procedure or whether watchful waiting or medication trials might be appropriate.
• Explore Alternative Screening Approaches: Mention emerging options like the finasteride trial to your doctor. Ask whether you might be a candidate for medication-based screening that could reduce PSA levels and potentially avoid biopsy altogether.
• Understand the Risks and Benefits: Biopsies carry infection risk, bleeding, and pain. Weigh these procedural risks against the actual likelihood that you have clinically significant cancer that requires treatment.

The scale of unnecessary biopsies in the United States is substantial. With 1.5 million procedures performed annually, even a modest reduction in unnecessary biopsies could spare hundreds of thousands of men from procedural complications and the psychological burden of a cancer diagnosis that may never threaten their health.

This research reflects a broader shift in how doctors approach prostate cancer screening. Rather than defaulting to biopsy whenever PSA levels rise, clinicians are increasingly asking whether a biopsy is truly necessary for each individual patient. The finasteride trial represents one concrete attempt to answer that question and offer men a less invasive alternative that might achieve the same screening goal.